ThermoFisherScientific - Custom and Bulks
Pharma Focus Europe
Worldwide Clinical Trials - Oncology

Walden Biosciences Announces Collaboration with Leading Genetic Epidemiologist to Investigate suPAR's Causal Role in Chronic Kidney Disease

Tuesday, May 14, 2024

Walden Biosciences, Inc. (Walden), a biotechnology company focused on developing therapies for kidney disease, has partnered with the Primula Group to utilize genetic data from individuals with chronic kidney disease (CKD). Led by Dr. Dipender Gill of Imperial College London, the collaboration aims to explore the role of elevated suPAR levels in kidney diseases.

Walden's Chief Scientific Officer, Dr. Alex Duncan, expressed excitement about the collaboration, emphasizing suPAR's impact on kidney tissues and its association with kidney dysfunction and disease progression. The goal is to advance clinical development of WAL0921, Walden's anti-suPAR antibody currently undergoing Phase 2 trials for CKD.

The study will investigate genetic variants within the PLAUR gene, which influences circulating suPAR levels and kidney function. Understanding these variants could lead to new therapeutic approaches targeting suPAR.

Dr. Gill highlighted the collaboration's potential to guide treatment strategies for kidney disease patients and identify new therapeutic avenues involving suPAR modulation.

Earlier this year, Walden completed a Phase 1+ clinical study of WAL0921, showing promising results in reducing free suPAR levels. Walden's CEO, Dr. Blaine McKee, is optimistic about the collaboration's ability to enhance understanding of suPAR's role in kidney disease and support ongoing clinical trials of WAL0921.



Oliver Healthcare Packaging Pharmaceutical SolutionsThermoFisher - Mastering API production at every scaleFuture Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Sartorius Webinar - Pave Your Weigh to Accurate Analytical ResultsEUROPEAN PHARMA OUTSOURCING SUMMIT 2024patheon - Revolutionizing Pharma